News
Gilead Sciences shows strong Q1 execution, pipeline momentum, and margin upside, led by HIV and PrEP launches. See why GILD ...
Gilead Sciences Inc. (NASDAQ:GILD) is one of the 11 most profitable NASDAQ stocks to buy now. On June 11, RBC Capital ...
Let’s just say you wake up one morning in The Handmaid’s Tale universe, stuck inside the color-coded hellscape that is Gilead ...
The ultraconservative dictatorship in which the series based on Margaret Atwood’s novel is set is becoming less and less unthinkable ...
Gilead Sciences Inc. closed 8.32% below its 52-week high of $119.96, which the company reached on March 10th.
Gilead underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold, which has paused ...
Explore more
The U.S. Food and Drug Administration has paused Gilead Sciences' trials testing a combination of two of its experimental HIV ...
The U.S. Food and Drug Administration has placed a clinical hold on Gilead Sciences' trials testing a combination of two of ...
'We are in a good spot': Gilead's new chief medical officer is committed to pipeline diversification
Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...
Gilead’s HIV treatment trials involving an investigational integrase strand inhibitor (GS-1720) and an investigational capsid inhibitor (GS-4182) have been put on clinical hold by the Food and Drug ...
Weeks ago, The Handmaid’s Tale came to an end after six seasons. While not every story found a tidy conclusion, we at least ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results